The North America tulathromycin market size is expected to reach USD 159.98 million by 2030, with a CAGR of 4.25%.
Tulathromycin belongs to the macrolide class of antibiotics. It is a triamilide macrolide with three charged nitrogens and a 15-membered macrolide structure (gamithromycin is also a 16-member molecule). It's made from azalide macrolides like azithromycin. It prevents bacterial protein synthesis by binding to the ribosomal 50S subunit and other macrolides. It is bacteriostatic but has bactericidal properties in vitro. Due to its positively charged molecule, it may penetrate gram-negative bacteria more quickly than other macrolide antibiotics.
Tulathromycin is used in cattle to treat BRD caused by M. haemolytica, P. multocida, and Histophilus somni (formerly Haemophilus Somnus). It is also effective in treating Mycoplasma bovis infections. When used in high-risk calves, it has also been used to prevent infections caused by these pathogens. It also treats Fusobacterium necrophorum and Porphyromonas levii-related bovine foot rot (interdigital necrobacillosis). A single dose effectively treats bovine infectious keratoconjunctivitis (Moraxella bovis).
It has been used in pigs to control and treat SRD caused by Actinobacillus pleuropneumoniae, Pneumophilus multocida, Bordetella bronchiseptica, Mycoplasma hyopneumoniae, and Haemophilus parasuis. Tulathromycin has been used to treat pulmonary abscesses in foals (off-label use).
Cattle respiratory disease, especially outbreaks of pneumonia in nursing dairy cattle, was reported to the AHL and the Ontario Animal Health Network on a regular basis (OAHN). Bovine respiratory disease (BRD) is a complex, multifactorial syndrome that is one of the cattle industry's major welfare and economic concerns.
Detection of BRSV is higher in the winter months. The proportion of positive BRSV PCR results climbed to 33% between October 2019 and January 2020, up from 24% in 2018/19 and 15% in 2017/18. During these four months, approximately the same number of BRSV PCR tests were done in all three winters.
BRSV is a leading cause of pneumonia in calves and adults. Acute herd outbreaks are frequently associated with significant morbidity. Mortality rates may be affected by the severity of co-infections with other diseases, such as Mannheimia haemolytica.
The FDA in the United States approved two generic tulathromycin injections in late 2021 to treat and control specific illnesses in both cows and pigs. BRD is treated with both Macrosyn and Increxxa. Furthermore, it is used to treat SRD in pigs caused by Actinobacillus pleuropneumonia, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae.
Tulathromycin is present in Macrosyn and Increxxa in the same concentration and dose structure as the supported drug item, Draxxin. In the coming years, the general interest in tulathromycin will likely be hampered by these two conventional medications.
The North America tulathromycin market can be broken down into three categories based on type: greater than 99.0%, 98.0% to less than or equal to 99.0%, and 98% or less. The sub-segment of the North America tulathromycin market is anticipated to hold the most significant market share throughout the projected period. Demand has increased across various industries, including materials and chemicals, for the highest possible quality of industrial valves. The current demand for tulathromycin is partly driven by the need to reduce the possibility of contamination. It is anticipated that the growing worry regarding the market and industry will drive the market for tulathromycin in the materials and chemicals sector.
Cattle, pigs, and other animals are the categories that make up this segment of the market for tulathromycin. Application valves for tulathromycin are among the most fundamental and essential components of the advanced technological world that we live in today. In the market for tulathromycin, it is anticipated that this market category will occupy the most significant market share.
The North America tulathromycin market is divided into the U.S., Canada, and Mexico, based on country.
Tulathromycin's primary market is North America. Despite housing only 5% of the population, the area controls a sizable portion of the overall market. The United States retains its hegemony in the region and on the global stage. Because of respiratory diseases, the cattle population in the United States decreased in 2019, increasing the market demand for tulathromycin.
Bovine respiratory disease is the primary cause of economic loss in the beef business in North America, as well as a major health concern in the dairy industry. Bovine respiratory disease is the primary cause of economic loss in the beef business in North America, as well as a major health concern in the dairy industry. Pathogenesis is usually caused by predisposing stress that weakens respiratory defence mechanisms and coincidental primary infection with one or more respiratory viruses. Viral infection and the host's response to it weaken defences and facilitate colonization of deeper pulmonary tissues by bacteria normally found in the nasopharynx, particularly members of the Pasteurellaceae family. This disease syndrome, also known as pneumonic pasteurellosis, has a multifactorial nature that is better captured by the name bovine respiratory disease complex (BRD). Catastrophic outbreaks or "wrecks" involving large numbers of animals typically occur a week to 10 days after calves are shipped to feedlots, giving rise to the alternative name "shipping fever." Still, isolated cases in home-reared calves and dairy animals are also recognized.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|